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Aim: Glukagon-like-peptide-1 (GLP-1) and -2 (GLP-2), produced by intestinal L-cells, are key hormones
regulating intestinal transit, secretion, absorption, and mucosal growth. We evaluated naïve fasting
serum GLP-1 and GLP-2 levels in pediatric intestinal failure (IF).
Methods: Fifty-five IF patients with median age 4.2 (IQR 1.3e12) years and 47 matched healthy controls
underwent measurement of fasting serum GLP-1 and GLP-2.
Results: Serum GLP-2 [19.9 (13.8e27.9) vs 11.6 (7.0e18.6) ng/mL, P < 0.001], but not GLP-1 [6.1 (4.0e15.7)
vs 6.4 (3.9e10.7) ng/mL, P ¼ 0.976], levels were increased in IF patients. Serum GLP-2 concentrations
were higher in patients with small bowel-colic continuity [21.1 (15.0e30.7) ng/mL] compared to patients
with an endostomy [10.4 (6.6e17.9) ng/mL, P ¼ 0.028], whereas no association with preservation of
ileum or ileocecal valve was observed. During PN delivery, GLP-2 inversely associated with remaining
small bowel length (r ¼ 0.500, P ¼ 0.041) and frequency of PN infusions (r ¼ 0.549, P ¼ 0.042). Serum
GLP-1 levels were lower in patients receiving PN currently [4.1 (2.8e5.1)] compared to patients, who had
weaned off PN [6.5 (5.1e21.1), P ¼ 0.005], and correlated positively with duration of PN (r ¼ 0.763,
P ¼ 0.002) and negatively with percentage parenteral energy requirement (r ¼ 0.716, P ¼ 0.006).
Conclusions: In pediatric IF, serum GLP-2 levels increase in patients with small bowel-colic continuity
proportionally to the length of resected small intestine. Increase in serum GLP-1 and GLP-2 levels par-
alleled reducing requirement for parenteral support. These findings support regulation of intestinal
adaption by GLP-2 and GLP-1 in children with IF.
© 2016 Elsevier Ltd and European Society for Clinical Nutrition and Metabolism. All rights reserved.1. Introduction
Intestinal failure (IF) results from a major bowel resection or
congenital defect, leading to decreased intestinal absorptive area
and malabsorption, rapid intestinal transit, and need for long-term
parenteral nutrition (PN) to sustain adequate nutrition, growth and
survival [1]. Following a massive small intestinal resection, intes-
tinal adaptation, which involves a series of changes in intestinal
morphology, function, and regulation, efforts to compensate for the
loss of functional intestinal surface area, allowing gradual weaning
of PN [2,3]. Intestinal adaptation is mediated by several endocrine
hormones, including glucagon-like peptides (GLP) 1 and 2ery, Pediatric Liver and Gut
niversity Central Hospital,
218, 00029 HUS, Helsinki,
utanen).
for Clinical Nutrition and Metabolsynthesized by enteroendocrine L-cells of the distal small intestine
and colon [4e6]. GLP-1 inhibits gastric emptying and small intes-
tinal and colon motility [7,8]. GLP-2 is shown to slow proximal
intestinal motility, increase mesenteric blood flow, reduce gastric
secretion, and to act as a trophic agent for the small intestinal
mucosa improving nutrient absorption [9e11]. In patients with IF,
lack of feed-stimulated GLP-2 response may lead to poor intestinal
adaptation [4,5,12]. Discovery of enterotrophic effects of GLP-2 has
led to novel emerging treatment options in patients with IF [13,14].
A GLP-2 analog teduglutide has been shown to improve nutrient
and fluid absorption, endorse mucosal hyperplasia, and decrease
PN requirement in IF patients [13,15,16].
In this study, we hypothesized that serum GLP levels are re-
flected by the extent and location of intestinal resection, intestinal
continuity and PN requirement in pediatric onset IF. To test these
hypotheses, we cross-sectionally measured fasting serumGLP-1 and
GLP-2 levels in patients with pediatric onset IF and in controls
matched for age and gender to investigate their relationships with
intestinal adaptation during PN delivery and after weaning off PN.ism. All rights reserved.
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2.1. Ethics
This study was approved by the Helsinki University Central
Hospital ethics committee and the Institutional Review Board. A
written informed consent was received from all patients and con-
trols or their caregivers before any procedures.
2.2. Patients
Medical records of all patients with pediatric onset IF treated by
our rehabilitation program in Children's Hospital, Helsinki Uni-
versity Hospital from 1984 to 2014 were reviewed. In total, 72
eligible patients were identified of which 55 (76%) patients
participated in this cross-sectional study, including clinical exam-
ination and laboratory tests. An informed written consent was
received from patients and/or their parents.
For this study, IF was defined as over 50% resection of the small
bowel or a duration of PN over 30 days [17,18], and patients with a
primary intestinal dysmotility disorder such asHirschsprungdisease
with less than 50% of age-adjusted small bowel length remaining
were categorized to short bowel syndrome group. Our management
protocol for IF has been reviewed recently elsewhere [19,20].
2.3. Controls
Forty-seven age and gender-matched healthy children and
young adults without any renal, endocrinological, hepatobiliary or
gastrointestinal disease, were used as controls. Their age [6.4 years
(4.2e12), P ¼ 0.091] and sex (boys:girls, 35:12, P ¼ 0.144) distri-
butions were comparable to patients.
2.4. Baseline data
Baseline patient data, including amount and composition of PN
during 3 months preceding serum GLP-1 and GLP-2 measurement,
surgical procedures and anatomy of the remaining bowel were





Age 4.2 (1.3e12) 1
BMI 18.5 (16.9e20.0) 2
Weight z-score 0.8 (1.5e0.0) 
Height z-score 1.0 (2.2e0.2) 
Duration of PN (mo) 9.5 (4.2e34) 1
Time after weaning off PN (y)
Weekly PN infusions 7
PN calories of total nutrition (%) 7
Time after last bowel resection (y) 2.9 (1.0e9.0) 0
SBS/dysmotility disorder (n) 48/7 1
Remaining bowel
Small bowel (cm) 47 (25e101) 3
Small bowel (%)a 26 (17e47) 2
Ileum (cm) 0 (0e5) 0
Colon (%)a 87 (57e100) 7
ICV preserved (n) 26 6
Small intestinal endostomy (n) 4 3
Serum Citrulline (umol/L) 22 (15e29) 1
Serum GLP-1 (ng/mL) 6.0 (4.0e16) 4
Serum GLP-2 (ng/mL) 20 (14e28) 1
Data are median (IQR). GLP; glukagon-like-peptide, SBS; short bowel syndrome.
P-values refer to comparisons between patient groups using Fisher's exact test or Mann
a %; percentage of remaining age-adjusted small bowel or colon length.small bowel and colon length was calculated based on age-
specific normal values [21]. The weight and height were
expressed as z-scores. Body-mass index (BMI, in kg/m2; weight
divided by the square of height) was calculated for adults and
Finnish reference value-based BMI-for-age was calculated for
children over two years of age [22].
2.5. Laboratory tests
Blood samples were drawn after overnight fast, prepared with
centrifugation and stored to20 C until analyzed. Quantification of
serum GLP-1 and GLP-2 were performed with the Human GLP-2
(YK141) and GLP-1 (YK160) EIA kits (Yanaihara Institute Inc., Shi-
zuoka, Japan)according to themanufacturer's instructions. The intra-
assay and inter-assay CV (%) were 4.7 and 9.6 for GLP-1 and 3.0 and
14.3 for GLP-2, respectively. Serum citrulline, a marker of enterocyte
mass, was measured by using an automatic amino acid analyser
(Biochromon 30 Physiological and Midas Autosampler, Biochromon
Limited, Cambridge, England) as described previously [23].
2.6. Statistical analysis
Descriptive statistics are expressed as median (IQR) unless
otherwise stated. For multiple comparisons KruskallWallis test was
used, followed by post hoc Mann Whitney U test when Kruskall
Wallis test reached statistical significance. For pairwise compari-
sons Mann Whitney U test and Fisher's exact test was used. Asso-
ciations were tested with Spearman rank correlation test. Statistical
significance was set at 0.05.
3. Results
3.1. Patient characteristics
Patient characteristics are shown in Table 1. Causes of IF
included necrotizing enterocolitis (n ¼ 23), midgut voluvulus
(n ¼ 10), small bowel atresia (n ¼ 9), extensive Hirschsprung's
disease (n ¼ 7), chronic intestinal pseudo-obstruction (n ¼ 5), and
gastroscisis (n ¼ 1). Patients currently on PN were younger, hadatients on PN Patients weaned off PN P-value
7 38
0 23 1.000
.0 (0.3e4.6) 7.7 (3.1e17) 0.001
0.0 (18.5e22.1) 18.3 (16.5e19.4) 0.181
1.0 (2.0e0.0) 0.8 (1.5e0.1) 0.056
1.5 (2.9e0.5) 0.7 (1.9e0.3) 0.431




.6 (0.2e2.9) 4.4 (2.4e14) <0.001
5/2 33/5 1.000
0 (18e60) 50 (31e108) 0.031
3 (14e29) 32 (21e50) 0.046
(0e4) 2 (0e18) 0.125
1 (22e100) 95 (68e100) 0.069
20 0.249
1 0.083
3 (10e23) 24 (18e30) 0.001
.1 (2.8e5.1) 6.5 (5.1e21) 0.005
9 (14e25) 20 (14e34) 0.571
Whitney U test. P-values <0.05 are marked bold.
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remaining absolute and age-adjusted small bowel length compared
to patients, who had weaned off PN median 3.9 years before the
study. Four patients had a small intestinal endostomy without colic
continuity. Fourteen of the patients had undergone autologous
intestinal reconstruction surgery, including serial transverse
enteroplasty and tapering enteroplasty, median 3.1 (0.2e10) years
before. Of them, six were currently on PN and eight had weaned off
PN. Other baseline data, including BMI, weight and height z-scores
were comparable between patients currently receiving PN and
patients weaned off PN.
3.2. Serum GLP-1 and GLP-2 levels in relation to controls, PN-
dependency and growth
Serum GLP-2 levels were similarly increased both in patients
currently receiving PN [GLP-1 4.1 (2.8e5.1); GLP-2 19 (14e25)] and
in patients who had weaned off PN [GLP-1 6.5 (5.1e21); GLP-2 20
(14e34)] when compared to controls [GLP-1 6.4 (3.9e10.7); GLP-2
11.6 (7.0e18.6)] (Fig. 1, Table 1). Serum GLP-1 levels were decreased
in patients currently receiving PN, when compared to patients, who
had weaned off PN and controls (Fig. 1).Fig. 1. Fasting serum glucagon-like-peptide-1 (GLP-1) and -2 (GLP-2) levels in pa-
tients currently receiving parenteral nutrition (PN), patients weaned off PN and
controls. The box plots display median, IQR, and range. P-values for Mann Whitney U
test between two groups are shown. Kruskall Wallis test P ¼ 0.017 for GLP-1 and
P ¼ 0.001 for GLP-2.Serum GLP-1 and GLP-2 levels associated with decreasing PN
dependency as serum GLP-1 level correlated negatively with per-
centage of daily parenteral energy and serum GLP-2 with frequency
of PN infusions (Fig. 2). During PN, serum GLP-1 levels correlated
positively with age (r¼ 0.794, P < 0.001), time after the latest bowel
resection (r ¼ 0.794, P < 0.001), and duration of PN (r ¼ 0.763,
P ¼ 0.002), whereas in controls both serum GLP-1 (r ¼ 0.294,
P ¼ 0.045) and GLP-2 (r ¼ 0.402, P ¼ 0.007) correlated negatively
with age.
In all patients, serum GLP-1 level correlated positively with
weight z-score (r ¼ 0.388, P ¼ 0.005). After weaning off PN, weight
z-score correlated positively with GLP-1 and GLP-2 (Fig. 3) and BMI
with GLP-1 (r¼ 0.380, P¼ 0.032). Height z-scorewas not associated
with serum GLP-1 or GLP-2 levels (P > 0.05 for both).
3.3. Serum GLP-1 and GLP-2 levels in relation to remaining
intestine
As shown in Fig. 4, serum GLP-2 concentrations were higher in
patients with small bowel-colic continuity [21.1 (15.0e30.7) ng/Fig. 2. Serum glukagon-like-peptide-2 (GLP-2) levels correlated with the amount of
daily parenteral calories and frequency of parenteral nutrition (PN) infusions.
Spearman rank correlations.
Fig. 3. After weaning off PN, weight z-score correlated with serum glukagon-like-
peptide-1 (GLP-1) and -2 (GLP-2) levels. Spearman rank correlations.
Fig. 4. In patients on PN, serum GLP-2 levels were inversely associated with the
remaining small bowel length. A Spearman rank correlation.
Fig. 5. Patients with small bowel-colic continuity had significantly higher serum
glukagon-like-peptide-2 (GLP-2) levels compared to patients with a small intestinal
endostomy or controls (A). Patients with ileum with and without ileum (B) and those
with or without ileocecal valve, ICV, (C) had comparable levels of serum GLP-2. P-
values for Mann Whitney U test between two groups are shown. The box plots display
median, IQR, and range. Kruskall Wallis test P < 0.001 for all.
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(6.6e17.9) ng/mL, P ¼ 0.028]. In patients on PN, serum GLP-2
levels were inversely associated with the remaining small bowel
length (r ¼ 0.500, P ¼ 0.041) (Fig. 4), but not with the per-
centage of remaining colon (r ¼ 0.279, P ¼ 0.197). However, serum
GLP-1 and GLP-2 levels were not significantly different between
patients with or without any remaining ileum or ileocecal valve
(Fig. 5). GLP-1 and GLP-2 levels were comparable between the
patients with an anatomical short bowel syndrome and the pa-
tients with a primary dysmotility disorder as an underlying eti-
ology of IF (data not shown). Previous autologous intestinal
reconstruction surgery had no significant effect on serum GLP-1,
and GLP-2 levels (data not shown). During PN, serum GLP-1
levels correlated positively with time after the latest bowel
resection (r ¼ 0.765, P ¼ 0.001). Serum GLP-1 or GLP-2 levels
showed no significant associations with serum citrulline levels
(r ¼ 0.111e0.203, P > 0.05 for all).
4. Discussion
In this cross-sectional study, our major findings were, first, that
fasting serum GLP-2 levels are increased in IF patients irrespective
of whether or not currently receiving PN and that fasting serum
GLP-1 levels are decreased during current PN-dependency, but
comparable to controls after achievement of full enteral nutrition
following weaning off PN. Secondly, fasting serum GLP-2 concen-
trations were markedly higher in patients with small bowel-colic
continuity than in patients with small intestinal endostomy pro-
portionally to the length of resected small intestine, which may
contribute to the positive effects of preserved colon on intestinal
adaptation. Our findings support the roles of GLP-1 and GLP-2 in
mediating intestinal adaptation after pediatric onset IF.
In animal models and in humans, GLP-2 acts as trophic agent for
intestinal mucosa and enhances intestinal nutrient and fluid ab-
sorption [9,10,24,25]. After massive bowel resection, serum GLP-2
levels correlatewith spontaneous intestinal adaptation in enterally
fed animals suggesting that GLP-2 mediates the intestinal adaptive
response to resection [11,25,26]. In PN-dependent neonates with
IF, Sigalet and colleagues reported positive correlation between
serum GLP-2 levels and tolerance of enteral feeds [12]. In adult
studies and preliminary data on children, GLP-2 and its long-acting
synthetic analog, teduglutide, have been shown to improve
nutrient and fluid absorption, weight gain, and to reduce PN re-
quirements [8,13,14]. In this study, serum GLP-1 levels were
decreased during PN, while serum GLP-2 levels were increased
irrespective of whether or not patients were currently receiving
PN. Whether the decreased serum GLP-1 levels during PN are
related to limited food intake and nutrient induced secretion of
GLP-1 remains unclear and require further studies. Serum GLP-2
levels were elevated not only during PN delivery but also after
weaning off PN. This suggests that GLP-2 is not simply associated
with the immediate adaptive response after resection, but is also
important in the maintenance of the adaptive response. Serum
GLP-1 and GLP-2 levels positively associated with decreasing PN
requirement as serum GLP-1 levels correlated negatively with
percentage of daily PN calories and serum GLP-2 with frequency of
daily PN infusions. These observations support the positive effects
of GLP-1 and GLP-2 on intestinal adaptation and tolerance of
enteral feeds in pediatric IF patients. Additional work on post-
prandial GLP levels are needed to increase our understanding how
meal-stimulated GLP secretion contribute intestinal adaptation in
children.
Preserved ileocecal valve and colon improve chances of weaning
off PN [3]. In adult short bowel patients with resected ileum, the
presence of residual colon associates with increased postprandialserum levels of GLP-1 and GLP-2 [4,5]. In contrast, in premature PN-
dependent neonates with IF, no association between the residual
colon and serum GLP-2 levels was observed [12]. In this study
among children with IF, the remaining small bowel length corre-
lated negatively with the increased serum GLP-2 levels suggesting
an enhanced adaptive response in patients with a shorter
remaining small bowel. Moreover, serum GLP-2 levels were
significantly higher in patients with preserved small bowel-colic
continuity than in patients with small intestinal endostomy and
fecal diversion, which underlines the importance of luminal nu-
trients and bile acids in stimulation of GLP-2 secretion from in-
testinal L-cells [6,11]. Notably, none of our patients were on total
PN, but received variable amount of enteral feeds in addition to
parenteral support. Based on our findings, the preserved colon was
the main source of fasting GLP-2, because preservation of the ileum
or the ileocecal valve had no significant effect on fasting serumGLP-
2 levels. In summary, elevated GLP-2 levels in IF children with
colonic continuity may contribute to the positive effects of a pre-
served colon on intestinal adaptation and the superior clinical
outcomes in this group of patients.
Serum GLP-2 levels remain elevated up to one month after in-
testinal resection in neonatal IF [12]. This suggests that GLP-2 is not
simply associated with the immediate adaptive response after
resection, but is also important in the maintenance of the adaptive
response [12]. Accordingly in the present study, serum GLP-2 levels
were elevated not only during PN delivery and also after weaning
off PN. Serum GLP-1 levels were decreased during PN, but elevated
to the control level after weaning of PN. Both GLP-1 and GLP-2
serum levels correlated positively with weight z-score. These re-
sults suggest an ongoing contribution of GLP-1 and GLP-2 to in-
testinal adaption process in patients with pediatric onset IF.
This study had some limitations, including the cross-sectional
study design, which provides association rather than prove of
causality. In addition, the number of patients with an endostomy
was limited and postprandial GLP levels were not measured. GLP-2
is secreted from ileal and colonic enteroendocrine L-cells in
response to both proximal enteric neuronal signaling and the
presence of luminal nutrients and bile acids. To better understand
the connections between meal-stimulated GLP secretion and in-
testinal adaptation, postprandial measurements of serum GLPs
would be important by providing mechanistic information of the
effects of enteral nutrition in weaned off patients compared to
patients on PN. Despite these limitations, this study provides new
clinical information on the GLP-1 and GLP-2 levels during intestinal
adaptation in pediatric onset IF.Statement of authorship
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